{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Induction+Phase&page=45",
    "query": {
      "intervention": "Induction Phase",
      "page": 45
    },
    "page_size": 10
  },
  "pagination": {
    "page": 45,
    "page_size": 10,
    "total_count": 2300,
    "total_pages": 230,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Induction+Phase&page=46&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Induction+Phase&page=44&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T07:54:25.218Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01326923",
      "title": "Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Cancer"
      ],
      "interventions": [
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Louisiana State University Health Sciences Center Shreveport",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2010-06",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2020-10-09",
      "last_synced_at": "2026-10-29T07:54:25.218Z",
      "location_count": 1,
      "location_summary": "Shreveport, Louisiana",
      "locations": [
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01326923"
    },
    {
      "nct_id": "NCT03520686",
      "title": "Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "NAI + Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "NAI + Nivolumab + Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAI",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAI",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAI",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin + Nab-paclitaxel + Atezolizumab + NAI",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Drug: Cisplatin/Carboplatin and Pemetrexed plus Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin/Carboplatin and Pemetrexed plus Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin and Paclitaxel plus Atezolizumab and Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin and Nab-paclitaxel plus Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2018-05-18",
      "completion_date": "2025-10-13",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-10-29T07:54:25.218Z",
      "location_count": 31,
      "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 28 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "El Segundo",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03520686"
    },
    {
      "nct_id": "NCT07169851",
      "title": "A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nausea",
        "Vomiting",
        "Drug-Related Side Effects and Adverse Reactions",
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "LY3537021",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care Antiemetic Therapies",
          "type": "DRUG"
        },
        {
          "name": "Background Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 204,
      "start_date": "2025-11-28",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-29T07:54:25.218Z",
      "location_count": 20,
      "location_summary": "Greenbrae, California • Irvine, California • Los Alamitos, California + 17 more",
      "locations": [
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07169851"
    },
    {
      "nct_id": "NCT03141151",
      "title": "Competency-based Approaches to Community Health",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity, Childhood"
      ],
      "interventions": [
        {
          "name": "COACH: Healthy Bodies",
          "type": "BEHAVIORAL"
        },
        {
          "name": "COACH: Strong Minds",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "3 Years to 5 Years"
      },
      "enrollment_count": 117,
      "start_date": "2017-05-16",
      "completion_date": "2018-08-31",
      "has_results": true,
      "last_update_posted_date": "2020-03-20",
      "last_synced_at": "2026-10-29T07:54:25.218Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03141151"
    },
    {
      "nct_id": "NCT00526669",
      "title": "Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms, Gastrointestinal Tract"
      ],
      "interventions": [
        {
          "name": "Lapatinib and Capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2008-03",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2016-01-29",
      "last_synced_at": "2026-10-29T07:54:25.218Z",
      "location_count": 8,
      "location_summary": "Loma Linda, California • Los Angeles, California • Washington D.C., District of Columbia + 5 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00526669"
    },
    {
      "nct_id": "NCT03640221",
      "title": "Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertension",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Ertugliflozin",
          "type": "DRUG"
        },
        {
          "name": "Hydrochlorothiazide 12.5mg",
          "type": "DRUG"
        },
        {
          "name": "Microneurography",
          "type": "DEVICE"
        },
        {
          "name": "SKNA recordings",
          "type": "OTHER"
        },
        {
          "name": "Static Handgrip",
          "type": "OTHER"
        },
        {
          "name": "Post-handgrip forearm vascular occlusion",
          "type": "OTHER"
        },
        {
          "name": "Testing of the Arterial Baroreflex Function",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "35 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2018-09-01",
      "completion_date": "2020-08-31",
      "has_results": false,
      "last_update_posted_date": "2020-01-14",
      "last_synced_at": "2026-10-29T07:54:25.218Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03640221"
    },
    {
      "nct_id": "NCT06954805",
      "title": "Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma",
        "Lymphoma, B-Cell"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "CAPP-seq",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Jennifer Amengual",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-04-14",
      "completion_date": "2028-04-14",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-10-29T07:54:25.218Z",
      "location_count": 2,
      "location_summary": "Stanford, California • New York, New York",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06954805"
    },
    {
      "nct_id": "NCT02647866",
      "title": "Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ulcerative Colitis",
        "Digestive System Diseases",
        "Colitis, Ulcerative",
        "Colitis",
        "Gastrointestinal Diseases",
        "Inflammatory Bowel Diseases",
        "Intestinal Diseases",
        "Colonic Diseases",
        "Autoimmune Disease",
        "Abdominal Pain"
      ],
      "interventions": [
        {
          "name": "KHK4083",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kyowa Kirin, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2016-06",
      "completion_date": "2018-10",
      "has_results": true,
      "last_update_posted_date": "2024-04-26",
      "last_synced_at": "2026-10-29T07:54:25.218Z",
      "location_count": 1,
      "location_summary": "Greenville, South Carolina",
      "locations": [
        {
          "city": "Greenville",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02647866"
    },
    {
      "nct_id": "NCT05010122",
      "title": "ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome",
        "Recurrent Acute Myeloid Leukemia",
        "Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Decitabine and Cedazuridine",
          "type": "DRUG"
        },
        {
          "name": "Gilteritinib",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2021-07-08",
      "completion_date": "2028-01-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-10-29T07:54:25.218Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05010122"
    },
    {
      "nct_id": "NCT00005793",
      "title": "A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Topotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "16 Years to 59 Years"
      },
      "enrollment_count": 41,
      "start_date": "1999-07",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2012-09-25",
      "last_synced_at": "2026-10-29T07:54:25.218Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005793"
    }
  ]
}